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ARTICLE
Inflammation mobilizes copper metabolism
to promote colon tumorigenesis via an
IL-17-STEAP4-XIAP axis
Yun Liao1,2,9, Junjie Zhao1,9, Katarzyna Bulek1,3, Fangqiang Tang1, Xing Chen1, Gang Cai1, Shang Jia 4,
Paul L. Fox5, Emina Huang 6, Theresa T. Pizarro7, Matthew F. Kalady6, Mark W. Jackson7, Shideng Bao6,
Ganes C. Sen1, George R. Stark6, Christopher J. Chang4,8 & Xiaoxia Li 1✉
Copper levels are known to be elevated in inflamed and malignant tissues. But the mechanism
underlying this selective enrichment has been elusive. In this study, we report a axis by which
inflammatory cytokines, such as IL-17, drive cellular copper uptake via the induction of a
metalloreductase, STEAP4. IL-17-induced elevated intracellular copper level leads to the
activation of an E3-ligase, XIAP, which potentiates IL-17-induced NFκB activation and sup-
presses the caspase 3 activity. Importantly, this IL-17-induced STEAP4-dependent cellular
copper uptake is critical for colon tumor formation in a murine model of colitis-associated
tumorigenesis and STEAP4 expression correlates with IL-17 level and XIAP activation in
human colon cancer. In summary, this study reveals a IL-17-STEAP4-XIAP axis through which
the inflammatory response induces copper uptake, promoting colon tumorigenesis.
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Cancer cells adopt a unique metabolic program to meet therelentless demand for proliferation and survival1. Thedistinct metabolism is now recognized as a hallmark for
cancer. Although tremendous strides have been made to under-
stand the glucose and lipid metabolism of cancer cells, how heavy
metals are utilized remains elusive. Early studies have repeatedly
documented altered levels of select heavy metals in malignant
tissue2,3. In particular, copper levels are elevated in sera and tis-
sues from patients with different solid tumors, including color-
ectal cancer4–11. In addition to its role as cofactor for key
metabolic enzymes, copper also directly contributes to tumor
growth by serving as a cofactor for signaling molecules such as
MEK1, which relays oncogenic BRAF signaling to ERK1/212–14.
Furthermore, copper chelation therapies have shown encouraging
efficacy in a phase II clinical trial for late-stage triple-negative
breast cancer15. This evidence collectively suggests a critical role
for copper in the progression of cancer.
A fundamental question concerning the role of copper in
cancer biology is how it is metabolized and selectively elevated in
malignant tissue. Copper is primarily stored in the liver, which
then releases it in a protein-bound form into the blood, and
excess copper is secreted in the bile16,17. As a toxic heavy metal,
copper levels are tightly regulated by a series of transporters,
chaperones, and enzymes. Tissue cells take copper up from serum
via the copper transporter Ctr118. Ctr1 transports cuprous (Cu I)
but not cupric copper (Cu II)19. This uptake mechanism entails
that Ctr1 works in conjunction with a metallo-reductase when
copper is available as Cu II. This two-step paradigm of copper
uptake shows that cancer cells need to manipulate the expression
of both transporter and reductase in order to regulate intracellular
copper levels16.
Intriguingly, the inflammatory response is the most well-
characterized physiological process that mobilizes biological
copper20–22. While the precise mechanism by which the immune
response re-routes copper trafficking is unclear, it is well docu-
mented that copper accumulates in inflamed tissues and con-
tributes critically to host defense against bacterial infection. On
the other hand, chronic inflammation is also a well-established
risk factor for cancer development, especially in the colon23,24.
Several proinflammatory cytokines, including IL-17, IL-6 and IL-
2225–28, are well-established tumor-promoting factors for colon
tumorigenesis and cancer progression. Thus, it is possible that
inflammatory cytokines, which are now known to have profound
and divergent potency in reprograming cell metabolism, may
contribute to copper accumulation in cancer cells by upregulating
machinery involved in copper uptake.
In this study, we report that STEAP4 is a key metallo-reductase
that promotes cellular copper uptake in response to chronic
inflammation during colon tumorigenesis. STEAP4 reduces
cupric copper to the cuprous form29,30. We found that STEAP4
overexpression significantly increases biologically available cop-
per in a colon cancer cell line, which correlates with enhanced
metastatic potential. In addition, STEAP4 was highly induced in
the inflamed colon, and deletion of STEAP4 from colonic epi-
thelial cells impaired copper accumulation and tumorigenesis in
the colon in a murine model of colitis-associated tumorigenesis.
Furthermore, STEAP4 was readily induced by tumor-promoting
cytokines such as IL-17, and the expression of STEAP4 was
required for IL-17-induced elevation of copper uptake. Mechan-
istically, STEAP4-mediated copper uptake sustained IL-17-
induced NFκB activation, while it suppressed caspase-3 activity
by activating XIAP. Our study has identified STEAP4 as a reg-
ulatory node for inflammation-mediated cellular copper uptake
and revealed a mechanism through which inflammation and
copper promote tumor progression.
Results
IL-17 promotes copper uptake via the induction of STEAP4.
STEAP4 is unique among its family members in that its expression
is regulated by proinflammatory cytokines31. Intriguingly, STEAP4,
but not any other component of the copper uptake machinery, was
readily induced in mouse colon organoids by the panel of cytokines
we tested (Fig. 1a). Analysis of STEAP4 promoter sequence revealed
binding sites for both NFκB and STAT3. To determine whether
STEAP4 was transcriptionally induced by NFκB or STAT3, we
analyzed the induction of STEAP4 expression by IL-17 (NFκB
activator) and IL-22 (STAT3 activator). STEAP4 was induced
within 4 h of IL-17 and IL-22 stimulation (Supplementary Fig. 1a).
Interestingly, pretreatment with actinomycin D, a transcription
inhibitor, abolished the induction of STEAP4 by IL-17 and IL-22,
suggesting that STEAP4 expression might be transcriptionally
regulated by NFκB and STAT3 activators. While IL-17 stimulation
increased the level of STEAP4, CTR1 is constitutively expressed in
the organoids (Fig. 1b). In vivo, IL-17 neutralization dramatically
suppressed STEAP4 expression in the inflamed colon tissue from
dextran sodium sulfate (DSS)-challenged mice (Supplementary
Fig. 1b–d). The colocalization of STEAP4 with Ctr1 suggested that
IL-17-induced STEAP4 expression might increase the cellular
copper uptake. To test this possibility, we measured the activity of
the superoxide dismutase 1 (SOD1), which utilizes copper as a
cofactor to scavenge free superoxide31 (Supplementary Fig. 1e), in
primary colon epithelial organoids. In order to determine the rate of
cellular copper uptake, we first treated the organoids with tetra-
thiomolybdate (TTM), a cell permeable Cu1+-specific chelator, to
deplete the intracellular copper and thereby quench baseline SOD
activity (Supplementary Fig. 1e). Afterwards, TTM was withdrawn
from the culture to allow the recovery of intracellular copper level,
which was monitored by measuring the SOD activity (Fig. 1c).
Interestingly, IL-17-primed colon organoids exhibited more rapid
recovery of SOD activity after TTM withdrawal, compared to
unprimed organoids (Fig. 1c). Importantly, STEAP4 deficiency
(St4 KO) significantly impaired the recovery of SOD activity,
despite IL-17 priming, suggesting that STEAP4 is required for the
IL-17-induced increase of copper uptake (Fig. 1d). To confirm the
elevation of intracellular copper in response to IL-17 stimulation,
we employed a small molecule-based fluorescent probe (CF4) that
emits a fluorescent signal in the presence of cuprous copper cations.
Live imaging using the CF4 probe indeed detected increased levels
of cuprous ions in response to IL-17-stimulation in wild-type but
not STEAP4-deficient cells and organoids (Fig. 1e, f). In addition,
IL-17-induced copper uptake was ablated in Ctr1-deficient cells
(Fig. 1g), suggesting that this process is dependent on the reductase
activity of STEAP4 that generates Cu1+ for Ctr1-mediated import.
Finally, using atomic absorption spectroscopy (AAS), we confirmed
that IL-17 stimulation induces cellular copper uptake into the
cytoplasm in a STEAP4-dependent manner (Fig. 1h, i). Taken
together, these data suggest that IL-17 drives copper uptake by
upregulating STEAP4 expression, in conjunction with the copper
transporter Ctr1.
STEAP4-mediated copper uptake promotes tumor growth. We
sought to identify the biological function of the inflammation-
driven cellular copper uptake. Given the well-documented role
of IL-17 signaling in driving epithelial cell proliferation and
survival in inflammation-associated tumorigenesis, we asked
whether STEAP4-mediated copper uptake promotes tumor
growth. To this end, we engineered an inducible STEAP4
expression system into the human colon cancer cell line Ls174t,
which robustly expressed Flag-tagged STEAP4 upon doxycy-
cline treatment (Fig. 2a). Consistent with previous reports29,30,
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overexpression of STEAP4 increased total intracellular copper
and iron pools in Ls174t cells (Fig. 2a). Interestingly, cellular
fractionation showed that the increased intracellular copper
in these cells was predominantly found in the cytoplasmic
fraction, while the elevated iron was more abundant in the
mitochondrial fraction (Fig. 2b). In support of the elevated
copper level in these cells, the activity of SOD1 was elevated
in response to STEAP4 overexpression, suggesting that the
increased intracellular copper was biologically functional
(Fig. 2c). Consistently STEAP4-overexpressing cells exhibited
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enhanced fluorescence when pulsed with active (CF4) but not a
control probe (Ctrl CF4) (Fig. 2d).
We asked whether the increased level of copper could enhance
tumor cell growth in vivo. We analyzed the growth kinetics of
xenografts derived from Ls174t cells with and without STEAP4
overexpression using the STEAP4-inducible Ls174t cell clones.
STEAP4 expression (Dox+) noticeably accelerated the growth of
xenografts implanted in the flank of the NSG mice (Supplemen-
tary Fig. 2a). Furthermore, the growth of STEAP4-expressing
tumors was suppressed by TTM treatment (Supplementary
Fig. 2b). Immunofluorescence staining showed that the accelera-
tion of tumor growth was associated with reduced caspase-3
activation and increased cell proliferation (Ki67+) in the tumor
tissue, which was also dampened by copper chelation (Supple-
mentary Fig. 2c, d). These data highlighted a critical role for
STEAP4-mediated copper uptake in promoting tumor growth.
Next, we evaluated the impact of STEAP4 expression on the
cancer metastasis and colonization in distant organ. We injected
STEAP4-overexpressing (Dox+) or control (Dox−) cells into the
spleens of immunocompromised mice to allow the formation
of liver metastases (Fig. 2f–j). Mice injected with STEAP4-
overexpressing Ls174t cells (Dox+, Supplementary Fig. 3a)
showed reduced survival compared to mice injected with control
cells (Fig. 2e). Consistently, in vivo bioluminescence and necropsy
revealed increased liver metastases in mice receiving STEAP4-
overexpresing cells compared to the controls (Fig. 2f, g). Notably,
liver metastases derived from STEAP4-overexpressing Ls174t
cells (Dox+) exhibited reduced apoptotic markers (cleaved
caspase 3 and TUNEL) and comparable Ki67 staining (Fig. 2h).
Importantly, TTM treatment reduced the burden of metastasis
from STEAP4-overexpressing cells (Fig. 2I and Supplementary
Fig. 3b, c). Additionally, TTM was able to further reduce the
burden of metastases when administered in conjunction with a
low dose of the chemotherapeutic agent 5-FU (Supplementary
Fig. 3d). Taken together, the data indicate that STEAP4-mediated
copper uptake plays a crucial role in promoting tumor growth.
STEAP4 sustains NF-κB activation and inhibits apoptosis.
Given the profound impact of IL-17 stimulation on cellular copper
uptake, we asked whether IL-17-induced STEAP4-mediated cop-
per uptake might have any impact on downstream IL-17 signaling.
To this end, we exploited the Ls174t cell line, which is highly
responsive to IL-17 in serum-restricted cultures. Because DMEM
does not contain copper and serum is the sole source of copper in
normal cell culture, this condition allowed us to also assess the
impact of copper deprivation and supplementation.
Consistent with increased intracellular copper levels, STEAP4
overexpression noticeably enhanced IL-17-stimulated ERK1/2
activation, which was completely subdued by copper chelation
with TTM (Fig. 3a). Conversely, copper supplementation sustained
IL-17-induced ERK1/2 in a STEAP4-dependent manner in Ls174t
cells (Fig. 3b) as well as in primary mouse colon organoids
(Fig. 3e). In addition, addition of copper also led to persisted
activation of NFκB in response to IL-17 stimulation in a STEAP4-
dependent manner (Fig. 3c, d and Supplementary Fig. 1f). Of note,
NF-κB and ERK1/2 activation were comparable between wild-type
and STEPA4-deficient cells at early time points in response to IL-
17-stimulation (Fig. 3f), consistent with the dependence of copper-
mediated enhancement of IL-17-induced NFκB and ERK1/2
activation on IL-17-induced STEAP4 expression.
In the intrasplenic injection model, STEAP4 overexpression was
associated with reduced caspase-3 activation in liver metastases
(Fig. 2h), and TTM/5-FU combined therapy induced dramatic
remission of the tumors and increased caspase-3 activation
(Supplementary Fig. 3d). To examine whether STEAP4-mediated
copper uptake exerts a direct impact on caspase-3 activation, we
examined the cellular response to 5-FU in the STEAP4-inducible
colon cancer cell line and in STEAP4-deficient colon organoids.
Consistent with our finding in the intrasplenic injection model,
STEAP4 expression protected cultured Ls174t cells from 5-FU-
induced caspase-3 activation (Fig. 3g). TTM treatment also restored
the drug sensitivity (Fig. 3g). In contrast, IL-17 stimulation
conferred upon both Ls174t cells and primary colon epithelial
organoids resistance to 5-FU-induced caspase-3 activation in a
STEAP4-dependent manner (Fig. 3h). Collectively, the data reveal
that STEAP4-mediated copper uptake can suppress stress-induced
caspase-3 activation.
Our mechanistic findings suggested that expression of STEAP4
might promote tumor growth via multiple downstream pathways.
To assess the contribution of STEAP4-mediated suppression of
caspase-3 activation to tumor growth, we used inhibitors against
Bcl-2 family proteins as a tool to induce caspase-3 activation. We
found that Ls174t cells were sensitive to s6384532, which
specifically inhibits Mcl-1. STEAP4 overexpression dampened
s63845-mediated cell death at low concentrations (~100 nM)
(Supplementary Fig. 4a). In vivo, although s63845 treatment
suppressed the growth of both STEAP4-expressing (Dox+) and
control (Dox−) xenografts, the s63845-treated STEAP4-expres-
sing (Dox+) xenografts showed faster growth rate compared to
control tumors treated with s63845 (Supplementary Fig. 4b, c).
Consistently, immunofluorescence staining revealed that while
s63845 treatment increased caspase-3 activation in both STEAP4-
expressing xenograft tissue and control tumor tissue, STEAP4
expression was able to reduce the frequencies of cleaved caspase-3-
positive cells in s63845-treated tumor (Supplementary Fig. 4d).
The data suggested that STEAP4-mediated suppression of caspase
3 was downstream of chemical-induced caspase-3 activation.
Fig. 1 IL-17 induces cellular copper uptake through induction of STEAP4. aWestern blots analysis for copper trafficking-associated proteins from lysates
of mouse colon epithelial organoids treated with different inflammatory cytokines for 8 h. Three independent experiments were done and representative
blots were shown. Untr untreated. b IL-17 primed or unprimed mouse colon organoids were stained for STEAP4 (St4), E-cadherin (E-cad) and Ctr1 and
integrin α. Scale bar, 100 µm. c SOD enzyme activity recovery from TTM inhibition in wild-type (WT) mouse organoids with or without 12 h of IL-17
priming. d SOD enzyme activity recovery in Steap4 wild-type (WT) and knockout (KO) organoids. e, f Fluorometric detection of intracellular copper in
primary mouse colon organoids (e) or Ls174t cells (f). CF4 copper Fluor-4 probe, Ctrl CF4 control probe. Scale bar,100 µm. n= 5 biologically independent
cell cultures. g Fluorometric detection of intracellular copper in Steap4 WT and Ctr1 knockdown cells. Cells were treated with or without IL-17 for 12 h and
copper were supplemented into the medium for 6 h in all the groups. Scale bar,100 µm. n= 5 biologically independent cell cultures. h Atomic absorption
spectroscopy measurement of copper content in Steap4 WT and KO Ls174t cells after copper addition. Cells were primed with or without IL-17 for 12 h and
then 10 µM Cu(II) were supplemented into the medium of the indicated group for 6 h. n= 5 biologically independent cell cultures. i Copper content in
cytosolic and mitochondrial fraction in Steap4 WT and KO cells, respectively. Cells were treated the same as described in panel (h). n= 5 biologically
independent cell cultures. Results were normalized to cell numbers. All data show mean ± SEM. Two-tailed Student’s t test was performed for panel e
(**P= 0.0057; ***P= 0.0004; ****P < 0.0001), f (***P= 0.0004; ****P < 0.0001), g (*P= 0.015; **P= 0.0027; ***P= 0.0004), h (*P= 0.0383; **P=
0.0022; ***P= 0.0009), i (***P= 0.0003; ****P < 0.0001; n.s., not significant). Data represent three independent experiments with similar results.
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Interestingly, the baseline proliferative capacity of tumor cells
in the xenograft from the flank model appeared to be lower than
that in the liver metastasis (Fig. 2h and Supplementary Fig. 2c).
Consequently, the proliferative impact of STEAP4 was more
pronounced in the xenograft implanted in the flank (Supplemen-
tary Fig. 2c). A key question is which of the STEAP4-mediated
downstream signaling served to increase cell proliferation.
Previous study has suggested that copper promotes oncogenic
ERK1/2 signaling by potentiating the kinase activity of MEK1, a
copper binding protein13. We indeed saw a copper-dependent
enhancement in ERK1/2 signaling in response to IL-17 stimula-
tion at late time points (Fig. 3a, b, e). Accordingly, treatment with
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the trametinib, a selective MEK1 inhibitor, suppressed STEAP4-
mediated enhancement in cell proliferation in vitro (Supplemen-
tary Fig. 4e). In addition to the sustained ERK1/2 activation,
STEAP4 expression also led to prolonged NFκB activation in a
copper-dependent manner (Fig. 3c, d). We then examined the
impact of STEAP4-mediated NFκB activation on tumor growth
using a selective IKKα/β inhibitor BMS-34554133,34. Pharmaco-
logical inhibition of NFκB activation blunted STEAP4-induced
cell proliferation in IL-17-stimulated Ls174t cells (Supplementary
Fig. 4e). In line with the in vitro data, inhibition of NFκB
activation reduced tumor cell proliferation and attenuated the
growth advantage conferred by STEAP4 expression in the
xenograft model (Supplementary Fig. 4f, g). However, inhibition
of NFκB did not normalize the growth kinetics (Supplementary
Fig. 4e, f). The residual tumor growth advantage was likely
contributed by the STEAP4-mediated suppression of caspase-3
activation. Of note, IL-17-stimulated Ls174t cell line that
expressed an enzymatically defective caspase-3 mutant (C163A)
remained susceptible to TTM treatment-induced reduction in
Ki67+ cells and suppression of tumor growth (Supplementary
Fig. 5a–g), highlighting a caspase-3-independent impact of
STEAP4 on NFκB in promoting tumor growth.
STEAP4-mediated copper uptake enhances the activity of
XIAP. While copper has been shown to directly impinge upon
the activation of MAPK kinases via MEK113, the mechanisms by
which copper regulates NF-κB and caspase-3 activation remain
elusive. From the literature, we know that X-linked inhibitor of
apoptosis (XIAP) is an E3 ligase that plays a critical role in
mediating TAK1-dependent NF-κB activation35. XIAP also cat-
alyzes the transfer of K48-linked ubiquitin moieties to caspase 3
to mediate its proteasome-dependent degradation36,37. Interest-
ingly, a multitude of evidence suggests that the conformation of
XIAP can be regulated by copper: supplementation to recombi-
nant XIAP, that addition of copper to cell cultures induces a
characteristic shift in XIAP mobility on nondenaturing gel38, that
addition of cuprous cations to recombinant XIAP protein leads to
the formation of oligomers39, and that copper can rescue zinc
depletion-induced degradation of XIAP40. Furthermore, NMR
analysis indicates that certain cysteine residues in XIAP are sus-
ceptible to copper-mediated oxidation, thereby regulating the
oligomerization state of the protein41. These unique character-
istics of XIAP prompted us to examine whether both the
enhanced NF-κB activation and suppressed caspase-3 activity
might be mediated by altered XIAP function, caused by an IL-17-
induced, STEAP4-mediated increase in cellular copper uptake.
To test this hypothesis, we took advantage of the characteristic
downward shift of XIAP mobility in response to copper supple-
mentation in cell culture. We primed Ls174t cells with IL-17 to
induce STEAP4 expression and cellular copper uptake in the
presence of increasing doses of copper (II) and analyzed XIAP
mobility by the Western method. Strikingly, IL-17-stimulation
dramatically increased the mobility of XIAP protein (Fig. 4a). In
addition, overexpression of STEAP4 in Ls174t cells also enhanced
the downward shift of XIAP in response to copper (II) in a
STEAP4-dependent manner (Fig. 4b, c). These data reveal that IL-
17-induced STEAP4-dependent copper uptake has a major impact
on the modification and/or conformation of XIAP. Importantly,
copper supplementation failed to sustain IL-17-induced phosphor-
ylation of IκB in XIAP-deficient cells (Fig. 4d), and XIAP
deficiency rendered Ls174t cells highly sensitive to 5-FU-induced
caspase-3 activation (Fig. 4e), indicating that XIAP plays an
important role in the IL17-induced effects of copper in cancer cells.
Importantly, Ls174t cell line that expressed a caspase-3 mutant
(F381H) defective in the interaction with XIAP42 (Supplementary
Fig. 5h) exhibited elevated level of cell apoptosis (Supplementary
Fig. 5i). While TTM treatment increased the TUNEL activity in
IL-17-treated STEAP4-expressing cells with wild-type caspase 3,
it failed to further enhance cell death in cells that expressed
mutant caspase 3 (Supplementary Fig. 5i). Taken together, the data
indicate that STEAP4-mediated suppression of caspase-3 activation
was dependent on the XIAP−caspase-3 interaction. In sum, our
xenograft data collectively (Supplementary Figs. 4–5) supported
that the copper chelation-mediated reduction in tumor growth was
due to both reduced proliferative output and increased apoptosis.
To examine whether copper-mediated XIAP-dependent
signaling impact requires XIAP E3-ligase activity, we prepared
recombinant XIAP protein in the presence of copper (XIAP-Cu)
and in its absence. We then subjected the recombinant XIAP
proteins to an in vitro ubiquitination assay, using cleaved caspase
3 as a substrate (Fig. 4f). XIAP-Cu exhibited greatly enhanced
enzymatic activity compared to XIAP without copper. Previous
studies have shown that the E3-ligase activity of XIAP promotes
SOD1 activity via the ubiquitination of copper chaperone for
superoxide dismutase (CCS)43. We indeed observed that XIAP
deficiency reduced both basal and IL-17-induced SOD1 activity
(Fig. 4g). Interestingly, we found that XIAP was found in a
complex with SOD1 and CCS, and that this interaction was
disrupted by STEAP4 overexpression (Figs. 4h, i). Taken together,
the data reveal that IL-17-induced STEAP4 expression drives
cellular copper uptake, leading to enhanced E3-ligase activity
of XIAP. Increased XIAP E3-ligase activity results in a series of
Fig. 2 STEAP4-mediated copper uptake leads to tumor metastasis. a AAS measurement of total copper and iron content in STEAP4-inducible Ls174t
cells cultured in the presence and absence of doxycycline (Dox) in serum-free DMEM supplemented with 10 µM Cu(II) or 10 µM Fe(III). ***P= 0.0009;
****P < 0.0001 by two-tailed Student’s t test. n= 5 biologically independent cell cultures. b Copper and iron content in cytosol and mitochondrial fraction in
STEAP4-inducible clone treated as described for panel (a). ***P= 0.0009; ****P < 0.0001; n.s., not significant by two-tailed Student’s t test. n= 5
biologically independent cell cultures. c Kinetics of the recovery of SOD activity from TTM treatment in STEAP4-inducible clones cultured in the presence
or absence of Dox. Ctr, no TTM treatment. The experiment was repeated with 3 sets of biologically independent cell cultures. d Fluorometric detection of
intracellular copper. CF4 copper Fluor-4 probe (CF4); Ctrl CF4 control probe. Scale bar, 100 µm. n= 5 biologically independent cell cultures. **P= 0.0046
by two-tailed Student’s t test. e Survival analysis for mice injected with STEAP4-inducible Ls174t clone cultured in the presence or absence of Dox (P=
0.012 by log-rank test, n= 9). f Metastatic tumor burden assessed 30 days after intrasplenic injection of luciferase-expressing STEAP4-inducible clones.
Total flux photons were quantified in bar graph (n= 6 mice). **P= 0.0017 by two-tailed Student’s t test. g Total number of metastatic nodules per liver.
*P= 0.0151 by two-tailed Student’s t test, n= 9 livers. h H&E and immunofluorescent staining of paraffin sections of the liver metastasis. Scale bar, 100 µm.
(n= 5). *P= 0.0158 for Cleaved Caspase-3 (cCasp3) and P= 0.0251 for TUNEL by two-tailed Student’s t test. i Bioluminescence imaging of metastatic
tumor burden after treatment with different drugs. Quantification was done based on the total flux photons. n= 8 mice. *P= 0.0109 by two-tailed
Student’s t test. j Histology analysis for metastatic tumor tissues from mice receiving different treatments. Ki67, cleaved caspase-3 (cCasp3) were stained
and TUNEL assay was performed on paraffin sections. n = 5 biologically independent tumor tissues. Scale bar, 100 µm. *P= 0.0264 for TUNEL, *P=
0.0124 for Ki67; **P= 0.0040 for cCasp3 by two-sided Student’s t test. All data were presented as mean ± SEM. Experiments in (a−e) were repeated
three times; (f−j) were repeated twice. Data were not pooled.
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Fig. 3 Copper uptake mediated by STEAP4 sustains NF-κB activation and inhibits apoptosis. a Western blot analysis of STEAP4-inducible Ls174t cells
stimulated with IL-17 in the presence or absence of Dox and/or TTM. b Western blot analysis of wild-type (WT) and STEAP4 knockout (St4 KO) Ls174t
cells stimulated with IL-17 for indicated hours in the presence or absence of 10μesCu(II). c Western blot analysis for nuclear translocation of p65 in the
presence or absence of TTM under IL-17 treatment in WT and St4 KO Ls174t cells stimulated with IL-17 for indicated hours in the presence or absence of
10μabCu(II). d Densitometric quantification of (c). Error bar shows S.E.M. of quantification from three biologically independent cells. e, f Western blot
analysis of primary colon organoids from wild-type (WT) or STEAP4 knockout (St4 KO) mice stimulated with IL-17 for indicated hours in the presence or
absence of Cu(II). g Western blot analysis showed Steap4 overexpression inhibited apoptosis, which can be reversed by TTM. h 5-FU-induced cell
apoptosis in Steap4 WT and KO organoids primed or unprimed with IL-17. Unless specified otherwise, data represent three independent experiments with
similar results.
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IL-17-induced downstream responses, including sustained NF-κB
activation, increased SOD1 activation, and suppressed caspase-3
activity.
STEAP4 promotes colitis-associated colon tumorigenesis.
Previous studies have shown that STEAP4 is highly induced in
colon epithelial cells in a mouse colitis model. Indeed, we found
that DSS, widely used to trigger colitis in murine models, induced
robust STEAP4 expression in mouse colon, starting from day 5
(Fig. 5a). Furthermore, the level of the copper chaperone CCS
(Fig. 5a), which inversely correlates with the level of functional
copper, was dramatically reduced as STEAP4 expression was
increased. In addition, DSS treatment also induced the char-
acteristic shift of the XIAP protein in colonic epithelial cells
(Fig. 5b). Collectively, the data indicate that there is a concerted
influx of copper in the mouse colon during intestinal inflam-
mation. IL-17 has been shown to play a protective role on the
integrity of intestinal epithelium by promoting tissue repair in
response to DSS challenge44,45,27 (Supplemental Fig. 1b–d). In
support of the role of STEAP4 as an IL-17 target gene, colonic
epithelial cell-specific STEAP4 deficiency resulted in aggravated
disease in response to DSS challenged in terms of weight loss and
increased gut permeability (Supplementary Fig. 6a–c). The
exacerbation of disease was associated with reduced gut epithelial
cell proliferation (Supplementary Fig. 6d). In light of the impact
of STEAP4 expression on tumor growth, we sought to determine
the role of STEAP4 in mouse colon epithelial cells in the colitis-
associated cancer model. To this end, we generated conditional
Steap4 knockout mice by flanking exon2 and exon 3 with two
loxp sequences. By breeding this strain onto a CDX2-CreERT2
background, we derived colonic epithelial cell-specific Steap4
knockout mice (Fig. 5c, Steap4CKO). We then subjected the
Steap4CKO and littermate control mice to chemically induced
tumorigenesis (the AOM-DSS model). Steap4 deficiency resulted
in pronounced reduction of copper and iron accumulation in
enriched colonic epithelial cells (Fig. 5d, e), and the tumor burden
in the Steap4CKO mice was also reduced compared to their lit-
termate controls (Fig. 5f, g). Immunofluorescent analysis of the
AOM-DSS-induced tumors showed that STEAP4 deficiency
resulted in a reduced frequency of Ki67-positive and an increased
frequency of active caspase-3-positive tumor cells (Fig. 5h). To
determine whether increased copper uptake was required for
AOM-DSS-induced tumorigenesis, we administered copper che-
lation therapy to wild-type mice treated with AOM-DSS (Fig. 5i).
Therapy with TTM substantially reduced the final tumor burden
in the AOM-DSS model (Fig. 5j, k). Similar to tumors from
Steap4CKO mice, tumors from TTM-treated mice also showed
reduced Ki67 staining and increased caspase-3 activation (Fig. 5l),
indicating that copper influx into the colon is required for colitis-
promoted tumorigenesis.
IL-17-induced copper uptake contributes to chemoresistance.
Next, we sought to determine whether IL-17-induced STEAP4-
mediated cellular copper uptake contributes to colon cancer
progression in human. Consistent with a previous report46, we
found that STEAP4 was overexpressed in a subset of human
colon cancer tissues and correlated with worse prognosis for
human CRC (Fig. 6a and Supplementary Fig. 6e). Interestingly,
the expression of STEAP4 positively correlated with IL-17
staining in the same tissues (Fig. 6b), while it inversely corre-
lated with caspase-3 activation (Fig. 6c). This evidence led us to
think that IL-17-induced STEAP4-mediated copper uptake might
play an important role in sustaining tumor growth in response to
chemotherapeutic treatments. In support of this idea, we found
that the XIAP protein from colon cancer tissues but not normal
colonic epithelial cells exhibited the characteristic downward shift
in nondenaturing gels (Fig. 6d). Of note, the increased XIAP
mobility was detected in both primary cancers and in hepatic
metastases, indicating that the level of biologically functional
copper was higher in the malignant cells. Furthermore, IL-17
treatment activated copper uptake in cancer organoids generated
from patient-derived liver metastases (Fig. 6e). In addition, IL-17-
induced SOD1 activity and NF-κB activation were abolished by
TTM or an XIAP inhibitor (Fig. 6f). IL-17 signaling has been
previously shown to confer chemoresistance in colon cancer cells.
We have now found that IL-17-mediated resistance to the
caspase-3 activation that is induced by 5-FU was effectively
abolished by copper chelation with TTM or by addition of XIAP
inhibitor in patient-derived colon cancer organoids (Fig. 6g, h).
Taken together, the data show that IL-17-induced copper uptake
contributes to chemoresistance in human colon cancer.
Discussion
In this study, we provide genetic evidence supporting a critical
role of STEAP4 in cellular copper transport in response to
chronic inflammation during colon tumorigenesis. Deletion of
STEAP4 specifically from colonic epithelial cells significantly
reduces copper accumulation and attenuates colon tumorigenesis
in the AOM-DSS model. Conversely, copper chelation abolishes
enhanced hepatic colonization by colon cancer cells that over-
express STEAP4. Mechanistically, STEAP4 expression enhances
cellular copper uptake, activating the E3-ligase activity of XIAP,
resulting in sustained NF-κB activation, increased SOD1
maturation, and suppressed caspase-3 activity. In summary, this
study has identified a copper-dependent IL-17−STEAP4 axis that
promotes cancer growth and confers resistance to chemotherapy.
Although the metallo-reductase activity of STEAP4 has been
extensively characterized in vitro29–31, the pathophysiological
function of STEAP4 has remained elusive. A recent study from
Xue et al.46 has shown that STEAP4 overexpression in colonic
epithelia cells increased the amount of iron in mitochondria at
steady state and rendered mice susceptible to chemically induced
colitis and colon tumorigenesis. By employing a loss-of-function
approach, we found that both copper and iron accumulation were
impaired in the colonic epithelial cell-specific STEAP4-deficient
mice during the process of colon tumorigenesis. Importantly,
copper chelation abolished STEAP4-mediated cancer growth in
the xenograft model. In addition, copper chelation was sufficient
to suppress tumorigenesis in the AOM-DSS model. Consistent
with reduced copper accumulation in colon tissue, colonic epi-
thelial cell-specific deletion of STEAP4 significantly attenuated
colon tumorigenesis in the AOM-DSS model. Taken together,
these data demonstrate a critical role for STEAP4-mediated
copper uptake in tumor initiation and cancer progression.
Of note, STEAP4 is induced by inflammatory cytokines,
including IL-17. STEAP4 deficiency abolished IL-17-induced cop-
per uptake in cells, suggesting that STEAP4 expression is required
for inflammation-mediated mobilization of copper metabolism.
While previous studies have suggested that the mobilized copper is
utilized by immune cells to kill bacteria during infection47,48, our
study reveals a crucial role for increased copper influx as a promoter
of the survival of epithelial cells in response to inflammation. We
identified a copper-regulated protein, XIAP, as a critical mediator
linking cell survival and copper uptake. IL-17-induced incorpora-
tion of copper into XIAP led to enhanced E3-ligase activity,
resulting in sustained NF-κB activation, increased SOD1 activity,
and suppressed caspase-3 activation. These downstream responses
collectively contribute to the survival of tumor cells during
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inflammation-associated colon tumorigenesis and confer resistance
to chemotherapy-induced cell death.
The impact of copper on XIAP was first reported as an increase
in the electrophoretic mobility of XIAP protein38. We found that
IL-17 stimulation resulted in further enhancement of the shift in
mobility of XIAP when copper was supplemented in cell culture
media, indicating that increased cellular copper uptake can reg-
ulate XIAP modification and/or conformation. Of note, detection
of this characteristic shift required resolving protein lysates in
gradient polyacrylamide gels in Bis−Tris buffer (Materials and
methods)38,43. Two potential mechanisms could lead to the
copper-dependent increase of electrophoretic mobility. Because of
the multiple metal binding motifs in the XIAP protein40, copper
might bind to the protein directly, resulting in a conformational
change. However, structural studies have yet to demonstrate the
architecture of copper-bound XIAP. On the other hand, several
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reports have shown that the BIR domains of XIAP contain
multiple cysteine residues that are susceptible to copper-regulated
oxidation41,39, which could also account for the change in elec-
trophoretic mobility. Although the nature of copper-induced
XIAP shift remains unclear, we found that recombinant XIAP
expressed in the presence of copper exhibited enhanced E3-ligase
activity, indicating that copper can functionally impact XIAP.
Future studies are required to elucidate the mechanism for
copper-mediated regulation of XIAP structure and function.
An important question is how enhanced E3-ligase activity of
XIAP promotes these distinct downstream responses. XIAP is a
versatile protein with diverse roles in regulating cell death and
inflammatory response. While well known for its ability to acti-
vate NF-κB signaling35, XIAP is also an established E3-ligase for
the K48 ubiquitination of cleaved caspase 336,37. We found that
copper-bound XIAP exhibited enhanced E3-ligase activity for
cleaved caspase 3, which was abolished by copper chelation.
Furthermore, XIAP has also been reported to promote the
maturation of SOD1 activity via the ubiquitination of the copper
chaperone CCS. We detected an XIAP-SOD-CCS complex that
was regulated by STEAP4 expression. Considering the enhanced
E3-ligase activity of copper-bound XIAP in vitro, it is possible
that a STEAP4-mediated increase of cytosolic copper may trigger
the potentiation of XIAP-E3-ligase activity, resulting in enhanced
CCS ubiquitination and SOD1 maturation. Indeed, IL-17-induced
SOD1 activity was greatly reduced in STEAP4- or XIAP-deficient
cells. These data collectively support a central role for XIAP as the
mediator of downstream responses of the IL-17−STEAP4 axis.
It is important to note that STEAP4- or XIAP-deficiency had
no impact on the early-signaling responses induced by IL-17.
Rather, STEAP4 and XIAP are required for copper-dependent
sustained NF-κF activation in response to IL-17 stimulation.
Importantly, the E3-ligase activity of XIAP has been reported to
mediate the NF-κB activation that is induced by NOD activation
by ubiquitinating RIPK249,50. This sustained NF-κB activation
has important pathological implications. IL-17 is a weak activator
of NF-κB in cell culture models, which is in stark contrast to the
profound proinflammatory impact of IL-17 in vivo. Our data
suggest that the status of cellular copper metabolism may be a
critical determining factor for cellular responses to IL-17 stimu-
lation in vivo. Future studies are required to delineate additional
under-recognized pathophysiological impacts of inflammation-
mediated copper mobilization.
Methods
Animals. All animal experiments were conducted in accordance with IACUC
guidelines at the Cleveland Clinic Lerner Research Institute. Generation of Steap4
knockout mice (St4 KO) has been described in previous studies51,52. Steap4floxed/floxed
mice were generated on the C57BL/6 background at Cyagen Biosciences Inc. (Santa
Clara, California) using homologous recombination. CDX2-CreERT2 mice (Stock No:
022390) were purchased from the Jackson Laboratory. NOD/scid gamma (NSG) mice
were supplied by the Biological Resource Unit at the Cleveland Clinic from a colony
maintained in-house. To generate CDX2-CreERT2 Steap4floxed/floxed(Steap4CKO),
Steap4floxed/floxed mice was bred onto CDX2-CreERT2 background and gender-
matched littermates were used for all experiments.
Generation of inducible, knockdown and knockout cell lines. The colon cancer
cell line LS174T was used to generate all engineered clones in this study. To
generate the STEAP4-inducible clone, Flag-tagged human STEAP4 cDNA under
the control of Tet-responsive element was transduced into the Ls174t cells along
with tetracycline transactivator (tTA) cDNA using lentiviral infection. The infected
cells were dispersed into single cells and derived into independent clones. The
clones are validated for doxycycline-dependent expression of Flag-tagged STEAP4
with western blot and five independently validated clones were pooled for sub-
sequent experiments. To generate STEAP4 and XIAP knockout cells, guide RNA
sequences from the GeCKO (v2) library were used53. Specifically, 5′-TTGCATC
CAGTGCTCCTGAC-3′ and 5′-GCAGTAGGGTGGTCTTCTGG-3′ were used to
knockout out STEAP4; 5′-GCATCAACACTGGCACGAGC-3′ was used to
knockout XIAP. These guide RNA sequences were cloned into the pLenti-Crispr v2
vector54,55 and transduced into Ls174t cells by lentiviral infection. The infected
cells were dispersed into single cell to generate independent clones and the clones
were validated by capillary sequencing of their genomic DNA. Five independently
validated clones were pooled and knockout efficiency was further validated by
western blot (Supplementary Figs. 1a and 4d). Control cells were generated by
transducing Ls174t cells with the same pLenti-Crispr that carried no guide RNA.
To generate Ctr1 knockdown cells, control and Ctr1-targeting shRNAs were
delivered to the Ls174t cells by lentiviral infection. Infected cells were cultured in
selective medium for 48 h to enrich for transduced cells before being subjected to
treatment and analysis.
Mouse and human organoid culture. Mouse colon organoids were derived from
freshly isolated colonic crypts from wild-type or Steap4 knockout mice (St4 KO).
Freshly harvested colon tissue was minced and incubated in chelation buffer
(5.6 mM Na2HPO4, 8.0 mM KH2PO4, 96.2 mM NaCl, 1.6 mM KCl, 43.4 mM
Sucrose, 54.9 mM D-Sorbitol, 2 mM Ethylenediaminetetraacetic acid (EDTA) 1:500
and 0.5 mM Dithiothreitol (DTT) on ice for 40 min, followed by mechanical dis-
sociation. Released crypts were filtered through a 100 μm cell strainer and pre-
cipitated at 300 × g for 5 min at 4 °C. Organoids were cultured in Matrigel
(Corning, USA) under organoid culture medium containing 50% advanced
DMEM/F12 (Gibco, USA) and 50% of conditioned medium from L-WNR cells,
supplemented with 10 μM Y27632 (Caymen Chemicals), 10 μM SB431542 (Cay-
men Chemicals), 10% fetal bovine serum (FBS) and 2 mM glutamine. Deidentified,
discarded cancer tissue that was removed from colorectal cancer patient were
used to derive colon cancer organoids. Human colon cancer organoids were
established according to published protocol56 with minor modification. Briefly,
fresh colon tumor specimen was dissociated using an enzymatic cocktail consisting
of 1.5 mg/mL collagenase VI (Worthington Biochemical, USA), 20 mg/mL hya-
luronidase (Worthington Biochemical), 1 mg/mL DNase (Worthington Biochem-
ical) and 10 μM Y27632 (Caymen Chemicals) in advanced DMEM/F12 (Gibco).
Dissociated single cells were seeded into Matrigel and maintained in epidermal
growth factor-supplemented cancer organoid culture medium derived from the
L-WNR cell line56–58. Tissue collection and experiments involving clinical samples
were approved by the Cleveland Clinic Institutional Review Board (IRB#4134).
AOM/DSS-induced colon tumorigenesis. To induce Cre recombinase activity in
the colonic epithelial cells, tamoxifen was injected twice per week into 6-week-old
Steap4floxed/floxedCDX2-CreERT2 and littermate control mice prior to the
AOM-DSS treatment for 4 weeks. All mice regardless of their genotypes received
intraperitoneal (i.p.) injection of tamoxifen (100 mg/kg) every 2 days for a total
of 2 weeks. After tamoxifen treatment, 8-week-old mice were administered
with azoxymethane (AOM, Sigma-Aldrich) dissolved in 0.9% NaCl at a dose of
Fig. 5 STEAP4 promotes colitis-associated colon tumorigenesis. a Western blot analysis of colon tissue lysates from mice treated with DSS water for
indicated days. b Analysis of XIAP shift on colon tissue lysates from mice treated with DSS water for indicated days. c Construction of STEAP4 floxed/
floxed allele. d Copper and iron contents of colons from WT and colonic epithelial cell-specific knockout mice (Steap4CKO) treated with DSS. n= 5 mice.
*P= 0.0281 and **P= 0.0061 for Cu measurement; *P= 0.0186 and **P= 0.0063 for Fe measurement by two-tailed Student’s t test. e Copper and iron
contents in the cytosol fraction and mitochondrial fraction from the DSS-treated Steap4 WT and KO colon tissue. n= 5 mice. *P= 0.0107 for right panel;
**P= 0.0097 for left panel by two-tailed Student’s t test. f Macroscopic view of longitudinally opened colon from control (WT) and colon epithelial cells-
specific knockout mice. g Tumor numbers and tumor incidence from WT and Steap4CKO mice on AOM-DSS-induced colon cancer model. n= 8 mice.
**P= 0.0084 by two-tailed Student’s t test. h H&E staining and immunostaining for Ki67 and cleaved caspase-3 (cCasp3) from paraffin sections of tumors
of the indicated genotypes. Scale bar, 100 µm. n= 5 biologically independent tissues. *P= 0.0239 for Ki67; *P= 0.0454 for cCasp3 by two-tailed Student’s
t test. i Treatment schedule of TTM. j, k Tumor burden for TTM- or vehicle-treated Steap4 WT mice on AOM-DSS model. *P= 0.0232 for panel (j) (n=
7 mice); *P= 0.0241 for panel (k) (n= 3) by two-tailed Student’s t test. l Immunostaining of Ki67 and cleaved Caspase-3 from TTM- or vehicle-treated
colon tissue. n= 5 biologically independent tissues. *P= 0.0265 for cCasp3; **P= 0.0012 for Ki67 by two-tailed Student’s t test. Scale bar, 100 µm. All
data were shown as mean ± SEM. All experiments were repeated twice with consistent results. Data were not pooled.
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12.5 mg/kg body weight. Subsequently, the mice were treated with 3% dextran
sulfate sodium (DSS, MP Biomedicals) in drinking water for 5 days, 1 week after
azoxymethane injection, and then with regular water for 16 days. After three cycles
of DSS water treatment, tumor-bearing mice were sacrificed. Colon tumor numbers
were manually counted and tumor diameters were measured with a caliber. Typical
tumors were paraffin-embedded and sectioned at 5 μm thickness for slides. His-
tology analysis was carried out on hematoxylin-eosin (H&E)-stained or unstained
tumor sections. For the copper chelation experiment, TTM was given at 10 mg/kg
body weight per mouse through intraperitoneal injection 3 days a week until the
endpoint. Normal saline (0.9% NaCl) was given to the control group.
For IL-17 neutralization experiment, mice were first put on 3% DSS water and
antibody injection was initiated 2 days later. In vivo anti-mouse IL-17 (Bio X Cell,
Cat# BE0173) or anti-mouse IgG (Bio X Cell, Cat# BE0093) were given to mice
through i.p. injection every 3 days until endpoint with 200 µg/mouse dosage.
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Xenograft tumor model. To investigate tumor growth difference, each flank of
NSG mouse was subcutaneously implanted with 1 million engineered LS174T cells
in 100 µL cold phosphate-buffered saline (PBS)−Matrigel (Corning) mixture (1:1
ratio). Implanted mice were randomly assigned to each treatment group. Steap4
expression was continuously induced by Doxycycline in drinking water (2 mg/mL
with 1% sucrose). TTM (10 mg/kg, Sigma), S63845 (Mcl-1 inhibitor, 12.5 mg/kg,
Cayman, Cat# 21131) and BMS-34554133,34 (IKKα/β inhibitor,125 mg/kg, Sigma,
Cat# B9935) were administered through intraperitoneal injection every other day
after implantation. Normal saline was injected as the control group. Tumor size
was measured using caliber and was initiated 3 days after implantation. Tumor
volume was calculated as length/2 × (width)2.
Intrasplenic injection model. The metastatic potential of colon cancer cells was
evaluated using the intrasplenic injection-based xenograft model. Engineered
LS174T cells (1 × 106/mouse) were surgically injected into the spleens of NSG mice.
The spleens of host mice were removed after injection to avoid premature mortality
from excessive tumor growth in the spleen. All of the injected cells were transduced
with firefly luciferase under the control of a CMV-promoter for in vivo biolumi-
nescence imaging. To examine the impact of STEAP4 expression on the metastatic
capacity, STEAP4-inducible cells were grown in the presence or absence of dox-
ycycline for 48 h before injection, resulting in durable expression of exogenous
STEAP4 in the xenograft (Supplementary Fig. 7a). Therapeutic evaluation of
TTM and 5-FU (Sigma-Aldrich) was performed on NSG mice bearing established
xenografts derived from STEAP4-overexpressing LS174T cells. Treatment
was initiated 1 week after intrasplenic injection. TTM (10 mg/kg) and/or 5-FU
(25 mg/kg) was dissolved in normal saline and administered via intraperitoneal
injection on a weekly basis. Normal saline was used as a control. In vivo biolu-
minescence imaging was used to quantify the amount of colon cancer liver
metastasis 30 days after the initial injection of cancer cells prior to necropsy. Mice
were anesthetized, injected with D-luciferin (3 mg/20 g body weight, Promega) and
imaged under IVIS Spectrum in vivo imaging system (PerkinElmer Inc.).
Western blot and immunoprecipitation. Briefly, cells were washed with ice-cold
PBS three times and lysed in buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 12.5 mM β-glycerophosphate, 1.5 mM MgCl2, 10 mM NaF, 2 mM
DTT, 2 mM sodium orthovanadate, 2 mM Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA), and Protease Inhibitor Cocktail (Roche)). Cell
extracts were centrifuged at 12,000 × g for 10 min at 4 °C and the supernatants were
denatured in Laemmli buffer at 95 °C for 10 min. Samples are resolved by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
polyvinylidene fluoride membrane. Subsequently, the membrane was blocked with
5% nonfat milk for 1 h at room temperature and then probed with primary anti-
body at 4 °C overnight, followed by incubation with HRP-conjugated secondary
antibody at room temperature for 1 h. Bands were visualized by chemilumines-
cence with Enhanced Chemiluminescence. For immunoprecipitation, cell lysates
were incubated overnight at 4 °C with antibody plus protein A/G Sepharose beads
(GE Healthcare Life Sciences), followed by extensive washes with lysis buffer.
Precipitates were eluted by SDS loading buffer and analyzed by the western
blot. The following antibodies are used in western blot: STEAP4 (Proteintech
11944-1-AP, 1:500); DYKDDDDK (Cell signaling 14793S, 1:1000); SOD1 (Pro-
teintech 10269-1-AP, 1:1000); SOD1 (Santa Cruze sc-271014, 1:1000); Cleaved
Caspase-3 (Cell signaling 9661S, 1:1000); Caspase-3, (Cell Signaling 9662, 1:1000);
Ctr1 (Cell signaling 13086S, 1:1000); ATP7A (Thermofisher PA5-36558, 1:1000);
ATP7B (Santa Cruz sc-373964, 1:1000); CCS (Santa Cruz sc-55561, 1:1000); p-IκBα
(Cell signaling 2859S, 1:1000); p-ERK1/2 (Cell signaling 4370S, 1:1000); p-JNK1/2
(Cell signaling 9255S, 1:1000); P65 (Cell signaling 8242, 1:1000); p-P38 (Cell sig-
naling 4511S, 1:1000); Act1 (eBioscience 14-4040-80, 1:1000); XIAP (Cell signaling
14334S, 1:1000); Lamin (Santa Cruz sc-376248, 1:1000); Tubulin (Cell signaling
2144S, 1:1000).
XIAP shift assay. To detect the impact of copper on the electrophoretic mobility
of XIAP, treated cells were lysed in buffer containing 25 mM HEPES, 100 mM
NaCl, 10% glycerol, and 1% Triton X-100, and EDTA-free protease inhibitor
cocktail (Roche). The lysed samples were then resolved in NuPAGE™ 4–12%
Bis-Tris Protein Gels (Invitrogen), transferred to nitrocellulose membranes and
then analyzed following regular western blot procedures using anti-XIAP (Cell
Signaling Technology, Cat# 2042).
Nuclear fractionation assay. Nuclear extraction was performed based on man-
ufacturer’s protocol using Nuclei isolation kit (Sigma, Cat# DUC-101). Briefly, cells
from 10 cm dish were harvested in 1 mL of ice-cold Nuclei EZ lysis buffer. Cell
lysates were then transferred to 1 mL Eppendorf tube and was set on ice for 5 min.
Nuclei was collected by centrifugation at 500 × g for 5 min at 4°. After the cen-
trifugation, supernatant was aspirated to a new tube as cytosol fraction for future
use. The pellet was washed again in 1 mL Nuclei EZ buffer and then lysed directly
in SDS loading buffer for Western blots analysis.
SOD activity assay. Cells or organoids were first primed with IL-17 (50 ng/mL)
for 12 h, followed by TTM treatment for 12 h and then medium was changed with
DMEM plus 10% FBS to allow the SOD activity to recover. Treated cells were
harvested and pelleted at 4 °C. Cell pellets were lysed in SOD lysis buffer (10 mM
NaPi pH 7.8, 0.1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 50 mM NaCl, 10%
Glycerol) plus protease inhibitors. Samples were then resolved on a 10% native gel
and then immersed in SOD staining solution (47.6 mL, 1 M K2HPO4, 4.8 mL 1M
KH2PO4, 140 mg nitro blue tetrazolium, 105 mg Riboflavin in 1050 mL dH2O) plus
35 µL TEMED at room temperature for 1 h. Stained gel was washed with ddH2O
and scanned at 300dpi.
Live cell/organoids copper imaging. Copper sensor compound CF-4 and its
control probe ctrl-CF4 were provided by Prof. Christopher J. Chang (University of
California, Berkeley). Characterization of the probe has been reported in previous
publications59,60. For live imaging, cells or organoids were seeded in NuncTM glass-
bottomed dish (Thermofisher) and stimulated in regular culture medium. Treated
cells were rinsed twice with PBS and then incubated in phenol red free DMEM
supplemented with 10 μM CF4 or control probe for 20 min. After incubation, cells
were washed with warm PBS on the dish and then covered with warm phenol-free
DMEM for imaging. Confocal microscopy was performed in a CO2 chamber at
37 °C. Images were obtained on a Leica TCS SP8 laser scanning microscope at ×40
higher magnification with He-Ne laser and HyD hybrid detector (570−700 nm).
Images were analyzed using Image-Pro 7.0.
Atomic absorption spectroscopy. To measure copper level in culture cells, whole-
cell extracts were prepared from a minimum of 5 million cells using 1% SDS buffer
and rigorous sonication. Total protein concentration of cell lysates was measured
for each sample using Bradford Assay. The protein concentrations were later used
as normalizing factor for total copper and iron measurement. Cell lysates were
dissolved in nitric acid at 60 °C for 4 h and immediately subjected to atomic
absorption spectroscopy (AAS). A flame or graphite furnace AAS instrument was
used to determine the total copper abundance in the sample. Concentration
standards prepared with CuCl2 or Fe2(SO4)3 in nitric acid was used to calibrate the
standard curve for every experiment.
To determine copper and iron level in mitochondria and cytoplasm, tissue or
cell mitochondria were isolated using the Mitochondria Isolation Kits from
Thermofisher (Cat# 89874 and Cat# 89801) according to the manufacturer’s
instruction. Cytosolic fraction, prepared as a byproduct, was saved for copper and
iron quantification. For determination of copper and iron content, total
mitochondria pellets or 500 mL of cytoplasmic fraction was dissolved or diluted in
nitric acid at 60 °C for 4 h before being subjected to AAS. The total copper and iron
level was normalized to total cell number.
Immunohistochemistry. Mouse tissue was fixed with 10% formalin overnight and
then kept in 70% ethanol at 4 °C until processed into paraffin tissue blocks by AML
Laboratories (Saint Augustine, Florida). Paraffin sections were subjected to heat-
induced epitope retrieval, as recommended by the antibody manufacturer before
staining. Deparaffined, epitope-retrieved sections were blocked with 10% normal
donkey serum and then incubated with primary antibody overnight. On the second
day, the sections were washed with 0.05% Tween PBS followed by incubation with
Fig. 6 IL-17-induced copper uptake contributes to chemoresistance in human colon cancer. a Immunostaining for STEAP4 expression in human normal
colon and tumor colon tissue. Representative staining is shown. Scale bar, 200 µm. n= 117 biologically independent tissues from different patients. ***P=
0.0007 by two-tailed Student’s t test. b, c STEAP4, IL-17 and cleaved Caspase 3 (cCasp3) were stained on consecutive sections of the same case. Staining
intensity of IL-17 and cCasp3 was plotted as a function of STEAP4 intensity. Linear regression was performed to derive the trend line, r and P value. Dotted
curve indicates 90% confidence interval. Scale bar, 200 µm. n= 117 biologically independent tissues from different patients. d Analysis of XIAP shift on
tissue lysates from paired normal (N), tumor (T) and metastatic tissue (M) of the same colon cancer cases. e IL-17-induced copper uptake measured by
fluorescence probe in colon cancer organoids. n= 5 biologically independent cells. **P= 0.0015 by unpaired two-tailed t test. Scale bar, 100 µm.
f, g Copper and XIAP are required for sustaining IL-17-induced NF-κB activation (f) and suppression of 5-FU-induced caspase-3 cleavage (g). h In-gel SOD1
activity assay on human colon cancer organoids. All data were presented as mean ± SEM. Experiments in (a−c) were performed once over 117 cases
(tissue microarray). Other data represent three independent experiments with similar results.
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secondary antibody and streptavidin-HRP for histochemistry and fluorescence-
conjugated secondary antibody. Staining was visualized with HRP-substrate
chromogen, DAB (3, 3-diaminobenzidine) (BD Pharmingen) or DAPI. The fol-
lowing primary antibodies were used for staining presented in the study: Ki67 (Cell
Signaling Technology 12202, 1:200), Cleaved Caspase 3 (Cell Signaling Technology
9661, 1:300), STEAP4 (Proteintech, 11944-1-AP,1:100), IL-17A (R&D Systems,
MAB317, 1:300), DYKDDDDK (Cell Signaling, 14793S, 1:300), Ctr1 (Novus Bio-
logicals NBP2-36573, 1:100), TUNEL assay (Sigma, 11684795910).
Protein purification and in vitro ubiquitination assay. Codon optimized full-
length human XIAP cDNA was cloned into pET28s vector. Recombinant proteins
were expressed in BL21 competent Escherichia coli and purified with Ni-NTA
agarose (Thermo Fisher Scientific). When indicated, CuCl2 (10 µM/mL) was added
to the bacteria suspension prior to IPTG-induction. The purified proteins were
further desalted and concentrated with Ultra Centrifugal Filter (Millipore). Purity
of the recombinant protein was assessed by Coomassie blue staining (Supple-
mentary Fig. 7b). For in vitro ubiquitination assay, K48-only ubiquitin, E1, E2
(UbcH5B) were purchased from Enzo Lifesciences; cleaved caspase-3 was pur-
chased from R&D Systems. The E3-ligase reaction was carried out in 10 mM
Mg/ATP solution with 100 µM K48-only ubiquitin, 5 µM recombinant cleaved
Caspase-3, 100 nM E1, 1 µM E2 enzyme (UbcH5B) and 1 µM recombinant XIAP.
Quantification and statistical analysis. Statistical significance was determined
using two-tailed Student’s t test when comparing the mean of two groups. No
adjustment was made for analyses based on Student’s t test. For growth kinetics
analysis, two-way ANOVA was applied to evaluate the significance between
treatment groups. Pearson correlation was used to analyze the correlation between
IL-17 and STEAP4 expression, between STEAP4 and cleaved Caspase-3. All data
were presented as the mean ± standard error of mean (SEM). All tests were two-
sided and P value less than 0.05 was considered to be statistically significant. All the
image quantifications were done by Image-Pro (version 7.0). All the statistics were
performed on Graphpad Prism 8.0.
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